amitriptyline, the psychiatric evaluation indicated moderate anxiodepressive symptoms, with a score of 10 on the Beck Depression Inventory and scores of 63 and 50, respectively, on the anxiety state and trait subscales of Spielberger's State-Trait Anxiety Inventory. There were no personality or psychotic disorders. The neurologic examination was normal. An EEG done before amitriptyline treatment was normal, without evidence of epilepsy. The patient had never complained about hearing loss, and there was no recent audiometric testing.
Tinnitus and auditory hallucinations have been associated with benzodiazepine discontinuation (7, 8) . Musical hallucinations are only rarely related to benzodiazepine consumption. They were reported in a 57-year-old man in good physical condition after he stopped taking triazolam for 8 nights (9) . Musical hallucinations were also reported in a 65-year-old woman whose tinnitus changed to musical hallucinations after the introduction of lorazepam and temazepam and then evolved into a rumbling noise when benzodiazepines were stopped (10).
In the absence of neurologic, otologic, or psychotic disorders, the fact that the hallucinations began with the introduction of lormetazepam and changed when the dosage was reduced with the introduction of amitriptyline suggests a causal relation to lormetazepam. The pathophysiological mechanism remains obscure. A convulsive mechanism seems unlikely. Lormetazepam's 10-hour elimination half-life makes any withdrawal phenomenon between 2 drug administrations unlikely. An interesting element is the qualitative change in the hallucination with the introduction of amitriptyline, because tinnitus is reported by about 1% of patients receiving tricyclic antidepressants (11) . The continued symptoms after the drugs were stopped could suggest that some undetected predisposing oto-neurologic factors facilitated the appearance of the hallucination François Curtin, MD, MPhil Charles Remund, MD Geneva, Switzerland
Bupropion-Methylphenidate Combination and Grand Mal Seizures
Dear Editor:
I report a case of grand mal seizures emerging in an adolescent boy being treated with combined bupropion and methylphenidate for attention-deficit hyperactivity disorder (ADHD) symptoms.
This 14-year old, 50-kg,white youth was brought to the emergency room following an episode of tonic-clonic movements, perioral cyanosis, and loss of consciousness. The episode lasted for more than a minute, and subsequently, the patient was somnolent and confused. He had no history of seizures or any other medical condition predisposing him to seizures.
The patient had been in treatment with methylphenidate 60 mg daily when bupropion was introduced to target dysphoric symptoms. The initial bupropion dosage was 200 mg daily, increased to 300 mg daily. The patient experienced the seizure 4 weeks after the dosage increase. Bupropion was discontinued, and the patient has been maintained on methylphenidate and remained seizure-free for 12 months.
Bupropion has been associated with seizures in adult patients treated for depression (1) and smoking cessation (2) . Information about the risk of seizures in children treated with bupropion is limited. In a multisite, double-blind trial of bupropion in 72 school-age children, EEGs switched from normal to abnormal in 6 subjects (8.3%); none of the subjects experienced seizures (3). More recently, a case of seizures in a 10-year-old treated with combined bupropion and guanfacine was reported (4). Methylphenidate's reputation of lowering the seizure threshold originates from animal studies in which massive amounts (300 mg/kg) were used to determine the lethal dose. Available evidence suggests that stimulant treatment for ADHD symptoms in children with epilepsy maintained on effective anticonvulsant treatment does not produce increased seizure frequency, EEG changes, or difficulty regulating blood levels of anticonvulsants (5, 6) .
It is quite likely that, in the case presented, seizure onset is linked primarily to bupropion. However, it is also possible that the risk of seizures was amplified by the combination of bupropion with methylphenidate. Clinicians should exercise caution when treatment with a medication known to lower seizure threshold is augmented with other psychotropics. When prescribing bupropion alone, or combined with other drugs in children and adolescents, patients and parents should be advised of the potential seizure risk.
Abel Ickowicz MD, FRCPC Toronto, Ontario

The Association of Depressed Affect and Stroke in Institutionalized Canadians
Dear Editor:
Depression following stroke is common, with a reported prevalence ranging between 25% and 46% (1). Depression may adversely affect functioning, recovery, and survival and may increase the risk of stroke morbidity and mortality.
The Canadian National Population Health Survey (NPHS) has 2 components: a household component and an institutional component. A previous analysis of stroke data from the NPHS was based exclusively on the household component, and the number of subjects reporting stroke and depression was too low to support a statistical analysis (2) . Statistics Canada has now released the data for the institutional component, and it is now possible to evaluate the association between stroke and depression in a national sample of institutionalized adults.
The target population for the 1996-1997 NPHS institution survey included all long-term residents of health institutions in Canada, excluding the territories, Indian reserves, and Canadian Forces bases (3). Data collection was carried out by personal interview, where possible, or by proxy interview, when required because of illness or incapacity (59.1% of interviews were completed by proxy). The sample consisted of 2118 individuals representing a target population estimated at 222 967. The institutional response rate for this survey was 100% (n = 213), and the individual response rate was 88.9%. We used a single item to evaluate depression: "How would you describe yourself as being usually?" Subjects who responded "unhappy, with little interest in life" and "so unhappy that life is not worthwhile" were regarded as suffering from depression. The survey interview also included a question asking, "Do you suffer from the effects of a stroke, such as paralysis or speech problems diagnosed by a health professional?" Finally, an item asked whether the subject had been diagnosed with a mental disorder by a health professional. Statistical analysis employed procedures recommended by Statistics Canada to account for the survey sampling procedures.
Very substantial proportions in this population reported depression and stroke: 16.1% and 20.1%, respectively. Depression was approximately twice as common in those with stroke (22.7%; 95%CI, 21.5% to 23.9%) as in those without stroke (12.8%; 95%CI, 10.9% to 14.6%). The association was equally evident in men and women and persisted after stratification for age (that is, over or under age 70 years).
The major weakness of the NPHS institution depression data is the measurement of mood status, which is based on a single self-report item. To address this, we identified the subset of those subjects reporting depression who also reported having had a mental disorder diagnosed by a health professional; 5.4% of persons with stroke fell into this category (95%CI, 3.5% to 7.3%), compared with 2.9% of those not reporting the effects of a stroke (95%CI, 2.1% to 3.7%). 
Quetiapine and Neuroleptic Malignant Syndrome
Neuroleptic malignant syndrome (NMS) is a reported complication of treatment with the atypical neuroleptics clozapine, risperidone, and olanzapine (1,2). I report a case of NMS associated with quetiapine as the sole neuroleptic.
Case Report
Mr AB is a reclusive, single, white man aged 44 years. His initial paranoid psychotic symptoms began 19 years previously, during multimodal therapy for stage 3A Hodgkin's disease. For 3 years, he had been stable in the community on risperidone 4 mg daily, followed by olanzapine 20 mg daily for over 1 year prior to this episode. Six months before this admission, his olanzapine 20 mg daily was gradually tapered, with a view to his entering a ziprasidone trial. At 10 mg olanzapine his psychosis relapsed, and he was restabilized in hospital on quetiapine 400 mg and clonazepam 2.5 mg daily. Eight weeks after starting quetiapine, he suddenly and rapidly decompensated,
